Further patient enrollment in trials in the U.S., Japan and India was suspended by Medtronic, which was forced to reduce the value of the technology in its financial statements by $236 million. Rival manufacturers responded by winding down their efforts to develop competitor devices, though since then some firms — including Medtronic — have attempted to improve the technology and believe it eventually will be of value to some patients. Medtronic told ICIJ it now believes 2014 poor trial results were the result of flaws in the design of the trial, not in the effectiveness of the device.